Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels

Blood

Volumn 109, Issue 6, 2007, Pages 2430-2437

  Van Schooten, Carina J M ^a   Denis, Cécile V ^b,c   Lisman, Ton ^a   Eikenboom, Jeroen C J ^d   Leebeek, Frank W ^e   Goudemand, Jenny ^f   Fressinaud, Edith ^g   Van Den Berg, H Marijke ^a,h   De Groot, Philip G ^a   Lenting, Peter J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Dept Environ Med Natl Inst Publ HIth   (Norway)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIV LILLE   (France)

^g NANTES UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOPRESSIN; PEANUT AGGLUTININ; SIALIDASE; SIALOPROTEIN; SUGAR; VIRUS T ANTIGEN; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC DISORDER; GLYCOSYLATION; HUMAN; INCUBATION TIME; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; SURVIVAL; VON WILLEBRAND DISEASE;

EID: 33947238964     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-06-032706     Document Type: Article

References (42)

1. Sadler JE. New concepts in von Willebrand disease. Annu Rev Med. 2005;56:173-191.
2. Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost. 2003;1:1335-1342.
3. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424.
4. Verweij CL, Diergaarde PJ, Hart M, Pannekoek H. Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit. EMBO J. 1986;5:1839-1847.
5. Romani de Wit T, van Mourik JA. Biosynthesis, processing and secretion of von Willebrand factor: biological implications. Best Pract Res Clin Haematol. 2001;14:241-255.
6. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol. 1990;6:217-246.
7. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med. 2004;351:683-694.
8. Titani K, Kumar S, Takio K, et al. Amino acid sequence of human von Willebrand factor. Biochemistry. 1986;25:3171-3184.
9. Matsui T, Titani K, Mizuochi T. Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor: occurrence of blood group A, B, and H(O) structures. J Biol Chem. 1992;267:8723-8731.
10. Sodetz JM, Paulson JC, McKee PA. Carbohydrate composition and identification of blood group A, B, and H oligosaccharide structures on human factor VIII/von Willebrand factor. J Biol Chem. 1979;254:10754-10760.
11. Wagner DD, Mayadas T, Marder VJ. Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor. J Cell Biol. 1986;102:1320-1324.
12. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69:1691-1695.
13. Ellies LG, Ditto D, Levy GG, et al. Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands. Proc Natl Acad Sci U S A. 2002;99:10042-10047.
14. Stoddart JH Jr, Andersen J, Lynch DC. Clearance of normal and type 2A von Willebrand factor in the rat. Blood. 1996;88:1692-1699.
15. Samor B, Mazurier C, Goudemand M, et al. Preliminary results on the carbohydrate moiety of factor VIII/von Willebrand factor (FVIII/vWf). Thromb Res. 1982;25:81-89.
16. Samor B, Michalski JC, Mazurier C, et al. Primary structure of the major O-glycosidically linked carbohydrate unit of human von Willebrand factor. Glycoconj J. 1989;6:263-270.
17. Lisman T, Bongers TN, Adelmeijer J, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology. 2006;44:53-61.
18. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-649.
19. Goodeve A, Eikenboom J, Castaman G, et al. Phenotype and genotype of a cohort of families historically diagnosed with Type 1 von Willebrand Disease in the European study, molecular and clinical markers for the diagnosis and management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood. 2007;109:112-121.
20. Eikenboom JC, Matsushita T, Reitsma PH et al. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. Blood. 1996;88:2433-2441.
21. Hulstein JJ, de Groot PG, Silence K, et al. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood. 2005;106:3035-3042.
22. Lenting PJ, Westein E, Terraube V, et al. An experimental model to study the in vivo survival of von Willebrand factor: basic aspects and application to the R1205H mutation. J Biol Chem. 2004;279:12102-12109.
23. Sodetz JM, Pizzo SV, McKee PA. Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. J Biol Chem. 1977;252:5538-5546.
24. Lankhof H, van Hoeij M, Schiphorst ME, et al. A3 domain is essential for interaction of von Willebrand factor with collagen type III. Thromb Haemost. 1996;75:950-958.
25. Romijn RA, Westein E, Bouma B, et al. Mapping the collagen-binding site in the von Willebrand factor-A3 domain. J Biol Chem. 2003;278:15035-15039.
26. Borchiellini A, Fijnvandraat K, ten Cate JW, et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood. 1996; 88:2951-2958.
27. van Schooten CJ, Tjernberg P, Westein E, et al. Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost. 2005;3:2228-2237.
28. Hebert DN, Garman SC, Molinari M. The glycan code of the endoplasmic reticulum: asparagine-linked carbohydrates as protein maturation and quality-control tags. Trends Cell Biol. 2005;15:364-370.
29. Monlauzeur L, Breuza L, Le Bivic A. Putative O-glycosylation sites and a membrane anchor are necessary for apical delivery of the human neurotrophin receptor in Caco-2 cells. J Biol Chem. 1998;273:30263-30270.
30. Mitra N, Sinha S, Ramya TN, Surolia A. N-linked oligosaccharides as outfitters for glycoprotein folding, form and function. Trends Biochem Sci. 2006;31:156-163.
31. Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem. 1982;51:531-554.
32. Millar CM, Brown SA. Oligosaccharide structures of von Willebrand factor and their potential role in von Willebrand disease. Blood Rev. 2006;20:83-92.
33. Mohlke KL, Purkayastha AA, Westrick RJ, et al. Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase. Cell. 1999;96:111-120.
34. Matsui T, Hamako J, Ozeki Y, Titani K. Comparative study of blood group-recognizing lectins toward ABO blood group antigens on neoglycoproteins, glycoproteins and complex-type oligosaccharides. Biochim Biophys Acta. 2001;1525:50-57.
35. O'Donnell J, Boulton FE, Manning RA, Laffan MA. Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level. Br J Haematol. 2002;116:350-356.
36. Ju T, Cummings RD. Protein glycosylation: chaperone mutation in Tn syndrome. Nature. 2005;437:1252.
37. Felner KM, Dinter A, Cartron JP, Berger EG. Repressed beta-1,3-galactosyltransferase in the Tn syndrome. Biochim Biophys Acta. 1998;1406:115-125.
38. Nurden AT, Dupuis D, Pidard D, et al. Surface modifications in the platelets of a patient with alpha-N-acetyl-D-galactosamine residues, the Tn-syndrome. J Clin Invest. 1982;70:1281-1291.
39. Xia L, Ju T, Westmuckett A, et al. Defective angiogenesis and fatal embryonic hemorrhage in mice lacking core 1-derived O-glycans. J Cell Biol. 2004;164:451-459.
40. Haberichter SL, Balistreri M, Christopherson P, et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood. Prepublished on July 11, 2006, as DOI 10.1182/blood-2006-04-015065. (Now available as Blood. 2006;108:3344-3351.)
41. Casonato A, Pontara E, Sartorello F, et al. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood. 2002;99:180-184.
42. Brown SA, Eldridge A, Collins PW, Bowen DJ. Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process? J Thromb Haemost. 2003;1:1714-1717.